Curated News
By: NewsRamp Editorial Staff
May 18, 2026
GeoVax Raises $3M to Advance Mpox, COVID-19 Vaccines and Cancer Therapy
TLDR
- GeoVax raised $3M from institutional investors at $1.48/share, funding its pivotal mpox vaccine Phase 3 trial.
- GeoVax issued 2M shares plus warrants to raise $3M, with proceeds for working capital and general corporate purposes.
- GeoVax's funding advances vaccines for mpox and COVID-19, aiming to improve global health and biodefense preparedness.
- GeoVax's GEO-MVA vaccine targets mpox and smallpox, with a pivotal Phase 3 trial planned for late 2026.
Impact - Why it Matters
This financing enables GeoVax to advance critical vaccine and immunotherapy programs, including a pivotal Phase 3 trial for its mpox/smallpox vaccine (GEO-MVA) and next-gen COVID-19 vaccine (GEO-CM04S1), as well as its cancer therapy Gedeptin. For investors, it signals continued development of high-demand vaccines amid global health preparedness needs, potentially addressing unmet medical needs in biodefense and oncology.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, has announced a private placement financing of approximately $3 million. The company entered into a securities purchase agreement with existing institutional investors for the sale of 2,027,027 shares of common stock (or equivalents), along with Series A and Series B warrants to purchase up to an additional 2,027,027 shares each, both with an exercise price of $1.48 per share. The Series A warrants have a five-year term, while Series B warrants have an 18-month term. The offering is expected to close on May 19, 2026, subject to customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent. Proceeds will be used for working capital and general corporate purposes.
GeoVax’s pipeline includes GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox, which is advancing toward a pivotal Phase 3 trial in the second half of 2026. In oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity, having completed a Phase 1/2 trial in advanced head and neck cancer. Additionally, GEO-CM04S1, a next-generation COVID-19 vaccine candidate, is being evaluated in immunocompromised patients. The company maintains a global intellectual property portfolio and continues to explore strategic partnerships. This financing provides capital to support these programs as GeoVax progresses its clinical milestones.
The offering is being conducted under an exemption from registration under the Securities Act of 1933, and the securities have not been registered under the Act. GeoVax has agreed to file a registration statement with the SEC covering the resale of the shares and underlying common warrants. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities. For more information, visit www.geovax.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax Raises $3M to Advance Mpox, COVID-19 Vaccines and Cancer Therapy
